Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivatuzumab mertansine in CD44v6+ metastatic breast cancer
NCT02254005Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2002
- Primary completion
- Dec 2004
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bivatuzumab mertansine in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Maximum tolerated dose. Started Oct 2002; status: completed.
02
Drugs
bivatuzumab mertansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02254005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254005.